Merck Expects 2024 Adjusted EPS Of $7.94-$8.04 Compared To Prior Guidance Of $8.53-$8.65 And Consensus Of $8.16, Includes One-time Charges Totaling $0.77 Per Share For The Harpoon And Eyebio Acquisitions
Portfolio Pulse from Benzinga Newsdesk
Merck has revised its 2024 adjusted EPS guidance to $7.94-$8.04, down from the previous $8.53-$8.65 and below the consensus of $8.16. This revision includes one-time charges totaling $0.77 per share for the Harpoon and Eyebio acquisitions.
July 30, 2024 | 10:35 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Merck has lowered its 2024 adjusted EPS guidance to $7.94-$8.04, down from the previous $8.53-$8.65 and below the consensus of $8.16. This includes one-time charges of $0.77 per share for the Harpoon and Eyebio acquisitions.
The downward revision in EPS guidance is significant and below market expectations, which is likely to negatively impact investor sentiment and the stock price in the short term. The one-time charges from the acquisitions add to the negative outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100